메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Samsung Biologics reports third quarter 2025 financial results

Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion Recorded Q3'25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025. "Our third quarter results reflect the solid foundation we have built through operational excell
- 김갑성 기자
- 2025-10-28 14:50
Standard Foods Announces Strategic Partnership and Investment in Hello Health to Strengthen the Bridge Between Digital Health and Nutrition in Southeast Asia.

SINGAPORE, Oct. 28, 2025 -- Hello Health Group (HHG), Asia's leading digital health and wellness platform, and Standard Foods Group (SFG), a leading nutrition and health-related consumer goods company headquartered in Taiwan, are pleased to announce a strategic partnership, with SFG joining as a strategic investor in HHG's Pre-Series A investment round. This collaboration marks a significant milestone for both organizations as they unite their strengths to advance the future of digital health, nutrition, and preventive wellness across Southeast Asia. The partnership brings together SFG
- 김갑성 기자
- 2025-10-28 10:00
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC

SUZHOU, China, Oct. 28, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (PROC), not restricted by HER2 expression. This marks another accelerated review recognition for JSKN003 from an internationally authoritative regulatory agency, following two previous Breakthrough
- 김갑성 기자
- 2025-10-28 09:46
Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

EPALINGES, Switzerland, Oct. 28, 2025 -- Onward Therapeutics SA, a clinical stage oncology company, today announced that its French subsidiary, Onward Therapeutics France, has exercised its exclusive option and entered into a worldwide license agreement with Institut du Cancer de Montpellier (ICM), France, to further advance a breakthrough program in onco-metabolism. This license agreement builds upon the exclusive collaboration and option agreement signed between Onward Therapeutics France and ICM, Inserm and Université de Montpellier in June 2021, under w
- 김갑성 기자
- 2025-10-28 08:00
Nippon Shinyaku Selects LifeSphere® Safety

Japan-based Nippon Shinyaku has chosen LifeSphere MultiVigilance as new case processing database TOKYO, Oct. 28, 2025 -- ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that Nippon Shinyaku, Ltd. has selected its LifeSphere® Safety platform. Nippon Shinyaku sought a global single database and streamlined workflow to unify its domestic and international safety processes. The company selected LifeSphere® for its proven automation capabilities, successful track record of implementations an
- 김갑성 기자
- 2025-10-28 07:00
Vietnam Healthcare Summit 2025: Powering Transformation of Vietnam's Healthcare Landscape Through Innovation and Investment

HO CHI MINH CITY, Vietnam, Oct. 28, 2025 -- Vietnam Innovators Digest successfully hosted the Vietnam Healthcare Summit 2025 under the theme "Making Vietnam an Innovation Hub Through Healthcare", held at JW Marriott Hotel & Suites Saigon. The event gathered over 200 healthcare leaders, investors, policymakers, and experts both domestically and internationally, to engage in strategic dialogue on Vietnam's potential to become a regional hub for healthcare innovation. The morning sessions focused on patient-centered innovation and enhancing access to healthcare servi
- 김갑성 기자
- 2025-10-28 01:31
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion of its acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced laboratory services in the United States. This strategic acquisition strengthens Fibronostics' research and development position and reinforces its commitment to innovation in metabolic dysfunct
- 김갑성 기자
- 2025-10-27 22:46
The WEMP Foundation and Rafa Nadal Foundation are joining together to Support Total Wellbeing of Children and Youth through Play

HONG KONG, Oct. 27, 2025 -- The WEMP Foundation (WEMP, which stands for "Wellbeing", "EQ", "Mental Health", and "Parenting") and the Rafal Nadal Foundation (RNF) are delighted to announce their alliance for supporting total wellbeing of children and youth around the world through Play. Dr. Adrian Cheng, founder of The WEMP Foundation, and Mr. Rafael Nadal, founding patron of the Rafa Nadal Foundation, co-hosted "The Children Ball — A Night of Hope, Strength and Inspiration", which was held at Rosewood Hong Kong on 24th October 2025. They are r
- 김갑성 기자
- 2025-10-27 22:13
Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion of an End-of-Phase 2 meeting with US FDA for its Investigational New Drug SAP-001 for treatment of hyperuricemia with gout in adult patients who are refractory to conventional therapy. "This End-of-Phase 2 meeting is a crucial milestone for our refractory gout program" says Dr. Bing
- 김갑성 기자
- 2025-10-27 21:00
Kolmar Korea Selected for Government-Led 'AI Factory' Initiative -- Driving Innovation in K-Beauty Manufacturing

The only cosmetics company chosen by the Ministry of Trade, Industry and Resources for the "AI Factory" project Enables agile, small-batch, multi-product production to meet diverse client needs in real time SEOUL, South Korea, Oct. 27, 2025 -- Kolmar Korea announced that it has been selected as the sole cosmetics company to lead a government-funded AI Factory Alliance project organized by South Korea's Ministry of Trade, Industry and Resources (MOTIR). Through this initiative, the company aims to move beyond smart factory automation toward AI-driven manufacturi
- 김갑성 기자
- 2025-10-27 20:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분